Subcutaneous pembrolizumab reduces time demands for both the patient and clinician, all while providing a consistent efficacy ...

Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer ...

A first-line regimen involving pembrolizumab (Keytruda) and olaparib (Lynparza) significantly reduced the risk of disease ...

Nemvaleukin alfa is an investigational engineered fusion protein composed of modified interleukin-2 (IL-2) and the high-affinity IL-2 alpha receptor chain.

Merck has shared data from the pivotal Phase 3 trial evaluating the subcutaneous administration of pembrolizumab together ...

Merck’s pembrolizumab with berahyaluronidase alfa demonstrates noninferior PK compared to IV Keytruda in pivotal 3475A-D77 trial: Rahway, New Jersey Saturday, March 29, 2025, 10 ...

Pembrolizumab and XL888 in advanced CRC showed manageable safety, though limited responses and potential immunomodulatory ...

Pfizer's $25 support holds strong, with institutional buying signals and growth potential in oncology. Click here to read an ...

The addition of pembrolizumab to chemoradiotherapy improved survival outcomes for women with high-risk, locally advanced ...

Duska noted that the PD-L1 inhibitor pembrolizumab has shown efficacy in the treatment of recurrent or metastatic cervical ...

Trisha Wise-Draper, MD, PhD, discusses anticipated data on head and neck cancers and their potential impact on the field.

PR Newswire SAN FRANCISCO and SUZHOU, China, March 30, 2025 SAN FRANCISCO and SUZHOU, China, March 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a ...